Mili Nosik oral drops with fruit flavor, 15ml — Made in India — Free Delivery

Pharmacological properties

The preparation for systemic use in pathology of the nasal cavity. phenylephrine is a sympathomimetic agent that causes vasoconstriction by stimulating α-adrenergic receptors located in the postcapillary vessels and cavernous-venous sinuses of the nasal mucosa. the narrowing of the blood vessels reduces the blood supply to the nasopharyngeal mucosa and leads to a long-term reduction in its edema.

Chlorpheniramine (chlorpheniramine) maleate is an H1 receptor blocker. Has antiallergic effect, reduces the manifestations of exudation. Has a moderately pronounced sedative effect.

Phenylephrine is rapidly absorbed in the digestive tract. Distributed in various tissues and biological fluids of the body, metabolized with the participation of MAO in the intestinal wall and in the liver. Excreted in the urine.

Chlorpheniramine maleate is well absorbed in the digestive tract. The maximum concentration in blood plasma is reached within 1-4 hours after ingestion. It crosses the placenta and is excreted in breast milk. It is characterized by a high degree of binding to blood plasma proteins, is completely metabolized in the body, excreted mainly in the urine in the form of metabolites.

Indications

Nasal congestion, colds accompanied by rhinorrhea, lacrimation, constant sneezing; rhinopharyngitis of infectious and allergic etiology, hay fever (hay fever); other acute and chronic diseases of the upper respiratory tract: rhinitis, sinusitis, pharyngitis.

Application

Inside, using a graduated pipette inside the package for dispensing. children aged 1-3 years - 0.5 ml each, 3-6 years old - 1 ml each, 6-12 years old - 1.5 ml each, over 12 years old and adults - 1.5-2 ml each 3 times day. the maximum duration of treatment is 4–5 days.

Contraindications

Hypersensitivity to one of the components of the preparation, angle-closure glaucoma, increased risk of urinary retention due to diseases of the urethra and prostate gland, hypertension with severe course, coronary artery disease, simultaneous treatment with MAO inhibitors, age up to 1 year, i trimester of pregnancy.

Side effects

Although the sedative effect of chlorpheniramine is mild, some patients may experience drowsiness. dizziness, headache, insomnia, increased excitability, anticholinergic effect (dry mouth, pharynx, decreased visual acuity, constipation) are also possible. side effects due to phenylephrine include tachycardia, irritability and irritability, insomnia, anxiety, headache, irritation of the gastric mucosa. the use of sympathomimetics in some cases may be accompanied by such side effects as a feeling of fear, anxiety, anxiety, tremor, general weakness, pallor of the skin, speech disorders, dysuria, hallucinations, convulsions, depression of the central nervous system, arrhythmia and cardiovascular insufficiency with arterial hypotension.

Special instructions

Sympathomimetics are used with caution in ag, diabetes mellitus, ischemic heart disease, hyperthyroidism, increased intraocular pressure and prostatic hypertrophy.

During the period of preparation treatment, you should not drink alcohol or use sedatives (especially barbiturates), which enhance the sedative effect of antihistamines (chlorpheniramine maleate). If the disease is caused by a bacterial infection, treatment with the preparation is carried out simultaneously with antibiotic therapy.

While taking the preparation, the patient should avoid driving vehicles, working with machinery and other potentially hazardous activities.

Interactions

Due to the content of phenylephrine, the preparation should not be used simultaneously with other sympathomimetics or with MAO inhibitors due to the risk of developing ag. due to the content of chlorpheniramine, the preparation can enhance the effect of preparations that depress the central nervous system (anesthetics, hypnotics).

Overdose

Manifested by sleep disturbance, severe weakness, sweating, itching, skin rash, urinary retention, tremor, brady- or tachycardia, coma. symptomatic treatment. hemodialysis is ineffective.

Storage conditions

In a dark place at a temperature of 15-25 ° C.